基于磁共振成像、全肿瘤表观扩散系数值和HPV基因分型的IB-IV期宫颈癌同步放化疗后预后模型
该研究回顾性分析2007-2014年接受同步放化疗的300例IB-IV期宫颈癌患者,筛选134例有3.0T MR图像者,整合全肿瘤ADC直方图参数、HPV基因分型及临床变量构建预后模型。模型将低、中、高危组的总生存和无病生存显著分层(p<0.0001),且在训练集和独立测试集中预测能力均优于FIGO分期(p<0.0001)。
要点
- ADC10是同步放化疗宫颈癌患者ADC参数中最佳预后因子,阈值0.77×10-3 mm2/s。
- 整合组织学类型、ADC10、T/M分期和HPV状态的模型可显著分层低、中、高危组。
- 该模型对总生存和无病生存的预测在训练集和测试集中均优于FIGO分期。
核心结论
- 基于临床和影像数据整合的预后模型可作为预测IB-IV期宫颈癌同步放化疗后总生存和无病生存的有用临床生物标志物。
研究设计与样本
- 研究回顾性分析三个前瞻性收集的队列,共300例2007-2014年接受同步放化疗的IB-IV期宫颈癌患者,筛选134例在3.0T行MR检查者进行最终分析(年龄24-92岁,中位54岁)。数据集随机分为训练集(n=88)和测试集(n=46)用于模型构建和独立bootstrap验证。
诊断标准与关键数值
- 模型纳入非鳞癌类型、ADC10<0.77×10-3 mm2/s、T3-4期、M1期和高危HPV状态;低、中、高危组的总生存和无病生存显著分层(p<0.0001);模型对总生存和无病生存的预测在训练集和独立测试集中均显著优于FIGO分期(p<0.0001)。
临床应用与阅片要点
- 对IB-IV期宫颈癌同步放化疗患者,可基于治疗前3.0T MR的全肿瘤ADC10值(阈值0.77×10-3 mm2/s)、组织学类型、T/M分期和HPV状态进行风险分层,辅助预测总生存和无病生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop and validate a prognostic model of integrating whole-tumour apparent diffusion coefficient (ADC) from pretreatment diffusion-weighted (DW) magnetic resonance (MR) imaging with human papillomavirus (HPV) genotyping in predicting the overall survival (OS) and disease-free survival (DFS) for women with stage IB-IV cervical cancer following concurrent chemoradiotherapy (CCRT).
METHODS: We retrospectively analysed three prospectively collected cohorts comprising 300 patients with stage IB-IV cervical cancer treated with CCRT in 2007-2014 and filtered 134 female patients who underwent MR imaging at 3.0 T for final analysis (age, 24-92 years; median, 54 years). Univariate and multivariate Cox regression analyses were used to evaluate the whole-tumour ADC histogram parameters, HPV genotyping and relevant clinical variables in predicting OS and DFS. The dataset was randomly split into training (n = 88) and testing (n = 46) datasets for construction and independent bootstrap validation of the models.
RESULTS: The median follow-up time for surviving patients was 69 months (range, 9-126 months). Non-squamous cell type, ADC10 <0.77 × 10-3 mm2/s, T3-4, M1 stage and high-risk HPV status were selected to generate a model, in which the OS and DFS for the low, intermediate and high-risk groups were significantly stratified (p < 0.0001). The prognostic model improved the prediction significantly compared with the International Federation of Gynaecology and Obstetrics (FIGO) stage for both the training and independent testing datasets (p < 0.0001).
CONCLUSIONS: The prognostic model based on integrated clinical and imaging data could be a useful clinical biomarker to predict OS and DFS in patients with stage IB-IV cervical cancer treated with CCRT.
KEY POINTS: • ADC 10 is the best prognostic factor among ADC parameters in cervical cancer treated with CCRT • A novel prognostic model was built based on histology, ADC 10 , T and M stage and HPV status • The prognostic model outperforms FIGO stage in the survival prediction.
引用
- Lin G, Yang LY, Lin YC, et al. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy. Eur Radiol. 2018. PMID: 30051142. doi:10.1007/s00330-018-5651-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。